Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, its largest-ever deal, to deepen a commercial endocrinology portfolio. Vertex will pick up Crinetics’ launched acromegaly therapy Palsonify (paltusotine) and a late-stage congenital adrenal hyperplasia program, with the transaction expected to close in the third quarter of 2026 after board approval. Vertex plans to fund the purchase with cash and $4.5 billion of bridge financing committed by Bank of America and Morgan Stanley. The company said the combined assets could generate peak sales of more than $5 billion, positioning them as margin-accretive for Vertex’s specialty endocrinology focus. Analysts said the price underscores strategic urgency in rare endocrine disease commercialization. The Crinetics deal also lands as Vertex continues to scale a pipeline built around oral and receptor-targeted biology. Vertex estimates that Palsonify and atumelnant together carry a substantial revenue upside if late-stage development executes and payers support uptake in rare disease settings. For Crinetics, the acquisition provides an accelerated path from commercial execution to broader scale through Vertex’s infrastructure, while investors focus on integration timing and the trajectory of the CAH program into confirmatory and regulatory steps.